vTv Therapeutics announces three appointments to Scientific Advisory Board

vTv Therapeutics (VTVT) announced the appointment of Alfonso Galderisi, MD, PhD, Mark Evans, MD, Chantal Mathieu, MD, PhD, and Klara Klein, MD, PhD, to its Scientific Advisory Board. The SAB, composed of internationally recognized leaders in endocrinology, diabetes research, clinical trial design, and regulatory science, will continue providing strategic guidance on the development of cadisegliatin, which is currently being investigated in Phase 3 clinical trials as an oral adjunctive therapy to insulin for the treatment of type 1 diabetes. Alfonso Galderisi, MD, PhD is a pediatric endocrinologist and physician-scientist (Associate Professor) at Yale University who specializes in the metabolic physiology of preclinical type 1 diabetes. Mark Evans, MD is a Professor of Diabetic Medicine at the University of Cambridge, U.K. He is renowned for his work on hypoglycemia and contributions to the Hypo-RESOLVE consortium. Klara Klein, MD, PhD is an Assistant Professor at the University of North Carolina at Chapel Hill.